Difference between revisions of "Rizzo Lab Research"

From Rizzo_Lab
Jump to: navigation, search
(Influenza)
(Method development)
Line 40: Line 40:
 
==Method development==
 
==Method development==
 
* [[Method development]]
 
* [[Method development]]
 +
====DOCK development====
 +
 +
The Rizzo Group is a codeveloper of the DOCK program and contributed to the latest to releases:
 +
 +
The release v6.4, greatly improved the sampling behavior with the inclusion of internal energy during growth and minimization. 
 +
See [http://dock.compbio.ucsf.edu/DOCK_6/new_in_6.4.txt release notes]
 +
 +
The release v6.5 includes a new scoring function termed Footprint similarity score.
 +
See [http://dock.compbio.ucsf.edu/DOCK_6/new_in_6.5.txt release notes]
 +
 +
=====docking testset development=====
 +
 +
To facilitate the improvements to the DOCK codebase and docking protocols, our group has developed a docking testset for pose reproduction.
 +
 +
See Mukherjee, S.; Balius, T.E.; Rizzo, R. C. Docking Validation Resources: Protein Family and Ligand Flexibility Experiments. J. Chem. Inf. Model, 2010, 50, 1986-2000. [http://rizzo.ams.sunysb.edu/~rizzo/StonyBrook/publications/rizzo021.pdf PDF]
 +
 +
 +
=====docking scoring functions=====
 +
 +
Footprint similarity score is described in
 +
 +
Balius, T.E.; Mukherjee, S.; Rizzo, R. C. Implementation and Evaluation of a Docking-Rescoring Method Using Molecular Footprint Comparisons. J. Comput. Chem., 2011, 32, 2273-2289. [http://rizzo.ams.sunysb.edu/~rizzo/StonyBrook/publications/rizzo022.pdf PDF]

Revision as of 10:13, 14 September 2011

PLEASE NOTE THIS PAGE IS BEING UPDATED

HIV/AIDS

GP41

viral membrane fusion inhibitor development.

See the following papers.

Strockbine, B.; Rizzo, R. C. Binding of Anti-Fusion Peptides with HIVgp41 from Molecular Dynamics Simulations: Quantitative Correlation with Experiment. Proteins: Struct. Func. Bioinformatics, 2007, 67, 630-642. PDF

McGillick, B. E.; Balius, T.E.; Mukherjee, S.; Rizzo, R. C. Origins of Resistance to the HIVgp41 Viral Entry Inhibitor T20. Biochemistry, 2010, 49 (17), 3575-3592 doi:10.1021/bi901915g PMID: 20230061 WEB PDF

Cancer


EGFR and ErbB family

Epidermal Growth Factor Receptor (EGFR) is a drug target for treating several types of Cancers, Including Lung and breast cansers. We are instested in targeting the Tyrosine kinase domain.

See the following paper:

Balius, T. E.; Rizzo, R. C. Quantitative Prediction of Fold Resistance for Inhibitors of EGFR. Biochemistry, 2009, 48, 8435-8448. WEB PDF


MMPs

see the following paper:

Carrascal, N.; Rizzo, R. C. Calculation of Binding Free Energies for Non-zinc Chelating Pyrimidine Dicarboxamide Inhibitors with MMP-13. Bioorg. Med. Chem. Lett., 2009, 19, 47-50. PDF

Influenza

Neuraminidase

Chachra, R.; Rizzo, R. C. Origins of Resistance Conferred by the R292K Neuraminidase Mutation via Molecular Dynamics and Free Energy Calculations. J. Chem. Theory Comput., 2008 ,4, 1526-1540. PDF

Method development

DOCK development

The Rizzo Group is a codeveloper of the DOCK program and contributed to the latest to releases:

The release v6.4, greatly improved the sampling behavior with the inclusion of internal energy during growth and minimization. See release notes

The release v6.5 includes a new scoring function termed Footprint similarity score. See release notes

docking testset development

To facilitate the improvements to the DOCK codebase and docking protocols, our group has developed a docking testset for pose reproduction.

See Mukherjee, S.; Balius, T.E.; Rizzo, R. C. Docking Validation Resources: Protein Family and Ligand Flexibility Experiments. J. Chem. Inf. Model, 2010, 50, 1986-2000. PDF


docking scoring functions

Footprint similarity score is described in

Balius, T.E.; Mukherjee, S.; Rizzo, R. C. Implementation and Evaluation of a Docking-Rescoring Method Using Molecular Footprint Comparisons. J. Comput. Chem., 2011, 32, 2273-2289. PDF